End-Stage Renal Disease and Kidney Transplant in HIV-Infected Patients

Seminars in Nephrology

Volumn 28, Issue 6, 2008, Pages 581-584

  Sawinski, Deirdre ^a   Murphy, Barbara ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

CKD; ESRD; HIV; renal transplant

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; CYTOCHROME P450 3A4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; THYMOCYTE ANTIBODY;

AFRICAN AMERICAN; ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHRONIC KIDNEY DISEASE; ENZYME ACTIVITY; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION RATE; INFECTION RISK; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; T CELL DEPLETION; VIRUS LOAD;

GRAFT REJECTION; HIV INFECTIONS; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; TREATMENT OUTCOME; UNITED STATES;

EID: 55649107935     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2008.08.002     Document Type: Article

References (27)

1. CDC. HIV/AIDS Statistics and surveillance. Basic Statistics. www.cdc.org [Accessed 2008 May 1]
2. Selik R.M., Byers Jr. R.H., and Dworkin M.S. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 29 (2002) 378-387
3. El-Sadr W.M., Lundgren J.D., Neaton J.D., Gordin F., Abrams D., Arduino R.C., et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355 (2006) 2283-2296
4. US Renal Data System. USRDS 2007 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. 2007. www.usrds.org
5. Wyatt C.M., and Klotman P.E. Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection. Expert Opin Drug Saf 5 (2006) 275-287
6. Szczech L.A., Gange S.J., van der Horst C., Bartlett J.A., Young M., Cohen M.H., et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 61 (2002) 195-202
7. Schwartz E.J., Szczech L.A., Ross M.J., Klotman M.E., Winston J.A., and Klotman P.E. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 16 (2005) 2412-2420
8. Lucas G.M., Mehta S.H., Atta M.G., Kirk G.D., Galai N., Vlahov D., et al. End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS 21 (2007) 2435-2443
9. Choi A.I., Rodriguez R.A., Bacchetti P., Bertenthal D., Volberding P.A., and O'hare A.M. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol 18 (2007) 2968-2974
10. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
11. Tonelli M., Wiebe N., Culleton B., House A., Rabbat C., Fok M., et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17 (2006) 2034-2047
12. Choi A.I., Rodriguez R.A., Bacchetti P., Bertenthal D., Volberding P.A., and O'hare A.M. The impact of HIV on chronic kidney disease outcomes. Kidney Int 72 (2007) 1380-1387
13. Ahuja T.S., Collinge N., Grady J., and Khan S. Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. J Am Soc Nephrol 13 (2002) 1889-1893
14. Ahuja T.S., Collinge N., Grady J., and Khan S. Is dialysis modality a factor in survival of patients with ESRD and HIV-associated nephropathy?. Am J Kidney Dis 41 (2003) 1060-1064
15. Kumar MS, Khan SM, Ranganna K, Malat GE, Kumar AM, Jacobsen JM. In HIV+ patients with end stage renal disease (ESRD) kidney transplantation significantly prolongs long-term patient survival compared to chronic dialysis treatment. Abstract presented at: American Transplant Congress; 2008 May 31; Toronto, Canada.
16. El Sayegh S., Keller M.J., Huprikar S., and Murphy B. Solid organ transplantation in HIV-infected recipients. Pediatr Transplant 8 (2004) 214-221
17. Stock P.G., Roland M.E., Carlson L., Freise C.E., Roberts J.P., Hirose R., et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 76 (2003) 370-375
18. Roland M.E., Barin B., Carlson L., Frassetto L.A., Terrault N.A., Hirose R., et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 8 (2008) 355-365
19. Kumar M.S., Sierka D.R., Damask A.M., Fyfe B., McAlack R.F., Heifets M., et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 67 (2005) 1622-1629
20. Qiu J., Terasaki P.I., Waki K., Cai J., and Gjertson D.W. HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients. Transplantation 81 (2006) 1658-1661
21. Abbott K.C., Swanson S.J., Agodoa L.Y., and Kimmel P.L. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 15 (2004) 1633-1639
22. Frassetto L.A., Browne M., Cheng A., Wolfe A.R., Roland M.E., Stock P.G., et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 7 (2007) 2816-2820
23. Karpas A., Lowdell M., Jacobson S.K., and Hill F. Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506. Proc Natl Acad Sci U S A 89 (1992) 8351-8355
24. Franke E.K., and Luban J. Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology 222 (1996) 279-282
25. Heredia A., Amoroso A., Davis C., Le N., Reardon E., Dominique J.K., et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci U S A 100 (2003) 10411-10416
26. Margolis D.M., Kewn S., Coull J.J., Ylisastigui L., Turner D., Wise H., et al. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr 31 (2002) 45-49
27. Carter J.T., Melcher M.L., Carlson L.L., Roland M.E., and Stock P.G. Thymoglobulin-associated Cd4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant 6 (2006) 753-760